SIMPATHY Study: Specific Antibody Response to Typhim Vi Polysaccharide as a Surrogate Marker of Infectious Risk in Secondary Immunodeficiency Associated with B Cell Cancer
Journal of Clinical Immunology · 20.08.2026 · 46 (1)
DOI: 10.1007/s10875-026-02052-8 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Immunology, online erschienen am 20.08.2026. Verfasst von Alejandro Peixoto-Rodriguez und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Institute of Laboratory Medicine and IdISSC, Hospital Clínico San Carlos and IdISSC, Calle Profesor Martín Lagos S…. Hauptthemen laut MEDLINE: Polysaccharides, Bacterial, Antibodies, Bacterial, Typhoid-Paratyphoid Vaccines, Immunologic Deficiency Syndromes. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grifols.
Abstract (Originalsprache)
Recurrent and severe infections represent a major cause of morbidity and mortality of secondary immunodeficiency (SID) associated with B-cell lymphoproliferative syndromes (B-CLPD). Nevertheless, immunological evaluation and prophylactic interventions are often delayed until infectious complications occur. Early vaccination is therefore relevant not only because it provides protection during the initial phases of B-CLPD, but also because it enables the identification of patients at higher risk of infection. In this context, assessment of antigen-specific humoral response has been proposed as a useful biomarker for identifying patients with greater clinical vulnerability. We conducted SIMPATHY (Secondary Immunodeficiency Multicentric study on the Antibody Production to Typhi vaccine), a multicentre, retrospective, observational study including 128 individuals with B-CLPD, classified according to the presence or absence of severe and/or recurrent infections, as well as healthy controls. Specific IgG antibody responses to Streptococcus pneumoniae (13-valent conjugate, Prevenar), Salmonella typhi (Typhim Vi), and tetanus toxoid vaccines were assessed at baseline and 4-weeks after vaccination. Among 128 individuals analysed, patients with B-CLPD showed significant immunological and clinical differences compared to healthy controls, particularly in vaccine-specific antibody responses and lymphocyte subsets. B-CLPD patients with recurrent or severe infections exhibited markedly reduced pre-vaccination anti-pneumococcal ( p = 0.03) and post-vaccination anti-pneumococcal ( p = 0.001) and anti- Salmonella typhi Vi titers ( p = 0.1), highlighting impaired vaccine-specific antibody responses as potential predictors of infection risk. An immunological classification identified two subgroups within B-CLPD, predominant antibody defect and combined immune defect, with a trend toward higher respiratory infection rates in the latter, suggesting broader immune dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Institute of Laboratory Medicine and IdISSC, Hospital Clínico San Carlos and IdISSC, Calle Profesor Martín Lagos SN, Madrid, 28040, Spain.
- Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, Madrid, Spain.
- Basic Medical Sciences, Physiology. Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, 28660, Spain.
- Department of Immunology, Infanta Cristina Hospital, Badajoz, Spain.
- Department of Immunology, Ramón y Cajal Hospital, Madrid, Spain.
- Department of Immunology, La Paz University Hospital, Madrid, Spain.
Förderung
- Grifols
Zitieren
APA
Peixoto-Rodriguez, A., Melero, J., de Andrés, A., López-Granados, E., Dieli-Crimi, R., Jiménez-Huete, A., Bailey-Maldonado, R., Jiménez, C., Mayol-Hornero, E., Cuesta-Mínguez, C., Rodríguez-Sanz, A., Guzmán-Fulgencio, M., Ochoa-Grullón, J., Peña-Cortijo, A., Polo Zarzuela, M., Íñigo, B., Mateo Morales, M., Anguita-Mandly, E., Fernández-Arquero, M., …, & Sánchez-Ramón, S. (2026). SIMPATHY Study: Specific Antibody Response to Typhim Vi Polysaccharide as a Surrogate Marker of Infectious Risk in Secondary Immunodeficiency Associated with B Cell Cancer. Journal of Clinical Immunology, 46(1). https://doi.org/10.1007/s10875-026-02052-8
Vancouver
Peixoto-Rodriguez A, Melero J, de Andrés A, López-Granados E, Dieli-Crimi R, Jiménez-Huete A, et al. SIMPATHY Study: Specific Antibody Response to Typhim Vi Polysaccharide as a Surrogate Marker of Infectious Risk in Secondary Immunodeficiency Associated with B Cell Cancer. Journal of Clinical Immunology. 2026;46(1). doi:10.1007/s10875-026-02052-8
BibTeX
@article{PeixotoRodriguez2026,
author = {Peixoto-Rodriguez, Alejandro and Melero, Josefa and de Andrés, Ana and López-Granados, Eduardo and Dieli-Crimi, Romina and Jiménez-Huete, Adolfo and Bailey-Maldonado, Rodrigo and Jiménez, Carlos and Mayol-Hornero, Elsa and Cuesta-Mínguez, Cristina and Rodríguez-Sanz, Aránzazu and Guzmán-Fulgencio, María and Ochoa-Grullón, Juliana and Peña-Cortijo, Ascensión and Polo Zarzuela, Marta and Íñigo, Belén and Mateo Morales, Marta and Anguita-Mandly, Eduardo and Fernández-Arquero, Miguel and Benavente-Cuesta, Celina and Lavandera-Díaz, José Luis and Sánchez-Ramón, Silvia},
title = {SIMPATHY Study: Specific Antibody Response to Typhim Vi Polysaccharide as a Surrogate Marker of Infectious Risk in Secondary Immunodeficiency Associated with B Cell Cancer},
journal = {Journal of Clinical Immunology},
year = {2026},
volume = {46},
number = {1},
doi = {10.1007/s10875-026-02052-8}
}
EUVIMED